1. Hawker GA. Osteoarthritis is a Serious Disease. Clin Exp Rheumatol (2019) 37 Suppl;120:3–6.
2. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. JAMA (2018) 320:1360–72. doi: 10.1001/jama.2018.13103
3. Penatti A, Facciotti F, De Matteis R, Larghi P, Paroni M, Murgo A, et al. Differences in Serum and Synovial CD4+ T Cells and Cytokine Profiles to Stratify Patients With Inflammatory Osteoarthritis and Rheumatoid Arthritis. Arthritis Res Ther (2017) 19:103. doi: 10.1186/s13075-017-1305-1
4. Harasymowicz NS, Clement ND, Azfer A, Burnett R, Salter DM, Simpson AHWR. Regional Differences Between Perisynovial and Infrapatellar Adipose Tissue Depots and Their Response to Class II and Class III Obesity in Patients With Osteoarthritis. Arthritis Rheumatol (2017) 69:1396–406. doi: 10.1002/art.40102
5. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. Role of Proinflammatory Cytokines in the Pathophysiology of Osteoarthritis. Nat Rev Rheumatol (2011) 7:33–42. doi: 10.1038/nrrheum.2010.196
6. Woodell-May JE, Sommerfeld SD. Role of Inflammation and the Immune System in the Progression of Osteoarthritis. J Orthop Res (2020) 38:253–7. doi: 10.1002/jor.24457
7. Torices S, Julia A, Muñoz P, Varela I, Balsa A, Marsal S, et al. A Functional Variant of TLR10 Modifies the Activity of NFkB and may Help Predict a Worse Prognosis in Patients With Rheumatoid Arthritis. Arthritis Res Ther (2016) 18:221. doi: 10.1186/s13075-016-1113-z
8. Smolen JS, LandewéR, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR Recommendations for the Management of Rheumatoid Arthritis With Synthetic and Biological Disease-Modifying Antirheumatic Drugs: 2016 Update. Ann Rheum Dis (2017) 76:960–77. doi: 10.1136/ annrheumdis-2016-210715
9. Wang T, He C. Pro-Inflammatory Cytokines: The Link Between Obesity and Osteoarthritis. Cytokine Growth Factor Rev (2018) 44:38–50. doi: 10.1016/ j.cytogfr.2018.10.002
10. de Jong AJ, Klein-Wieringa IR, Andersen SN, Kwekkeboom JC, Herb-van Toorn L, de Lange-Brokaar BJE, et al. Lack of High BMI-Related Features in Adipocytes and Inflammatory Cells in the Infrapatellar Fat Pad (IFP). Arthritis Res Ther (2017) 19:186. doi: 10.1186/s13075-017-1395-9
11. Roemer FW, Jarraya M, Felson DT, Hayashi D, Crema MD, Loeuille D, et al. Magnetic Resonance Imaging of Hoffa's Fat Pad and Relevance for Osteoarthritis Research: A Narrative Review. Osteoarthritis Cartilage (2016) 24:383–97. doi: 10.1016/j.joca.2015.09.018
12. Jiang LF, Fang JH, Wu LD. Role of Infrapatellar Fat Pad in Pathological Process of Knee Osteoarthritis: Future Applications in Treatment. World J Clin Cases (2019) 7:2134–42. doi: 10.12998/wjcc.v7.i16.2134
13. Ioan-Facsinay A, Kloppenburg M. An Emerging Player in Knee Osteoarthritis: The Infrapatellar Fat Pad. Arthritis Res Ther (2013) 15:225. doi: 10.1186/ar4422
14. Cassetta L, Cassol E, Poli G. Macrophage Polarization in Health and Disease. ScientificWorldJournal (2011) 11:2391–402. doi: 10.1100/2011/213962
15. Sica A, Mantovani A. Macrophage Plasticity and Polarization: In Vivo Veritas. J Clin Invest (2012) 122:787–95. doi: 10.1172/JCI59643
16. Kontny E, Prochorec-Sobieszek M. Articular Adipose Tissue Resident Macrophages in Rheumatoid Arthritis Patients: Potential Contribution to Local Abnormalities. Rheumatol (Oxford) (2013) 52:2158–67. doi: 10.1093/ rheumatology/ket287
17. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is Associated With Macrophage Accumulation in Adipose Tissue. J Clin Invest (2003) 112:1796–808. doi: 10.1172/JCI19246
18. Boutens L, Stienstra R. Adipose Tissue Macrophages: Going Off Track During Obesity. Diabetologia (2016) 59:879–94. doi: 10.1007/s00125-016-3904-9
19. Murano I, Rutkowski JM, Wang QA, Cho YR, Scherer PE, Cinti S. Time Course of Histomorphological Changes in Adipose Tissue Upon Acute Lipoatrophy. Nutr Metab Cardiovasc Dis (2013) 23:723–31. doi: 10.1016/j.numecd.2012.03.005
20. Gericke M, Weyer U, Braune J, Bechmann I, Eilers J. A Method for Long-Term Live Imaging of Tissue Macrophages in Adipose Tissue Explants. Am J Physiol Endocrinol Metab (2015) 308:E1023–33. doi: 10.1152/ajpendo.00075.2015
21. Distel E, Cadoudal T, Durant S, Poignard A, Chevalier X, Benelli C. The Infrapatellar Fat Pad in Knee Osteoarthritis: An Important Source of Interleukin-6 and its Soluble Receptor. Arthritis Rheumatol (2009) 60:3374–7. doi: 10.1002/art.24881
22. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate Normalization of Real-Time Quantitative RT-PCR Data by Geometric Averaging of Multiple Internal Control Genes. Genome Biol (2002) 3:RESEARCH0034. doi: 10.1186/gb-2002-3-7-research0034
23. Ko HL, Wang YS, Fong WL, Chi MS, Chi KH, Kao SJ. Apolipoprotein C1 (APOC1) as a Novel Diagnostic and Prognostic Biomarker for Lung Cancer: A Marker Phase I Trial. Thorac Cancer (2014) 5:500–8. doi: 10.1111/1759- 7714.12117
24. Greenblatt MB, Sargent JL, Farina G, Tsang K, Lafyatis R, Glimcher LH, et al. Interspecies Comparison of Human and Murine Scleroderma Reveals IL-13 and CCL2 as Disease Subset-Specific Targets. Am J Pathol (2012) 180:1080–94. doi: 10.1016/j.ajpath.2011.11.024
25. Singh R, Yadav V, Kumar S, Saini N. MicroRNA-195 Inhibits Proliferation, Invasion and Metastasis in Breast Cancer Cells by Targeting FASN, HMGCR, ACACA and CYP27B1. Sci Rep (2015) 5:17454. doi: 10.1038/srep17454
26. Fukui S, Iwamoto N, Takatani A, Igawa T, Shimizu T, Umeda M, et al. M1 and M2 Monocytes in Rheumatoid Arthritis: A Contribution of Imbalance of M1/ M2 Monocytes to Osteoclastogenesis. Front Immunol (2017) 8:1958. doi: 10.3389/fimmu.2017.01958
27. Plebanczyk M, Radzikowska A, Burakowski T, Janicka I, Musialowicz U, Kornatka A, et al. Different Secretory Activity of Articular and Subcutaneous Adipose Tissues From Rheumatoid Arthritis and Osteoarthritis Patients. Inflammation (2019) 42(1):375–86. doi: 10.1007/s10753-018-0901-9
28. Thomas S, Fisher KH, Snowden JA, Danson SJ, Brown S, Zeidler MP. Methotrexate Is a JAK/STAT Pathway Inhibitor. PloS One (2015) 10: e0130078. doi: 10.1371/journal.pone.0130078
29. Gremese E, Alivernini S, Tolusso B, Zeidler MP, Ferraccioli G. JAK Inhibition by Methotrexate (and csDMARDs) may Explain Clinical Efficacy as Monotherapy and Combination Therapy. J Leukoc Biol (2019) 106:1063–8. doi: 10.1002/JLB.5RU0519-145R
30. Groom JR, Luster AD. CXCR3 Ligands: Redundant, Collaborative and Antagonistic Functions. Immunol Cell Biol (2011) 89:207–15. doi: 10.1038/ icb.2010.158
31. DegboéY, Rauwel B, Baron M, Boyer JF, Ruyssen-Witrand A, Constantin A, et al. Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism. Front Immunol (2019) 10:3. doi: 10.3389/ fimmu.2019.00003
32. Laragione T, Gulko PS. Liver X Receptor Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Invasiveness, Matrix Metalloproteinase 2 Activation, Interleukin-6 and CXCL10. Mol Med (2012) 18:1009–17. doi: 10.2119/molmed.2012.00173
33. Oishi Y, Spann NJ, Link VM, Muse ED, Strid T, Edillor C, et al. SREBP1 Contributes to Resolution of Pro-Inflammatory TLR4 Signaling by Reprogramming Fatty Acid Metabolism. Cell Metab (2017) 25:412–27. doi: 10.1016/j.cmet.2016.11.009